Agreement will bring first-to-market capabilities to eliminate line-of-sight dependency designed to improve simplicity and surgical flow
RAYNHAM, Mass.–(BUSINESS WIRE)–DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced a definitive agreement to acquire selective rights to develop, manufacture and commercialize Gemtrack technology across its Joints portfolio, including shoulder, hip and knee, for both navigation and robotic applications. Gemtrack is a proprietary tracking technology developed by MinMaxMedical (MMM), a Grenoble-based pioneer in medtech and surgical innovation.
Pending successful product development and regulatory approvals, DePuy Synthes aims to bring first-to-market Radiofrequency (RF) miniature tracker technology across joint reconstruction procedures, with the potential to establish a new industry standard for integrated image-guided and robotic-assisted Joint surgery within the VELYS™ Enabling Tech Portfolio.
Current robotics and navigation systems in orthopaedics mostly rely on infrared cameras, direct line-of-sight tracking, and invasive pins or bulky arrays attached to the patient. RF technology has the potential to eliminate the need for infrared cameras and line-of-sight dependence, reduce the reliance on invasive anchors, and enable continuous, highly accurate real-time tracking.
“Stéphane Lavallée and his companies have successfully collaborated with DePuy Synthes, including for the VELYS Robotic Assisted Solution for knee arthroplasty and the VELYS Active Robotic Assistance for spine,” said Namal Nawana, Worldwide President, DePuy Synthes. “This new collaboration will be applied broadly to the VELYS ecosystem to reduce the reliance on line-of-sight dependent navigation and offering the potential for improved navigation precision.”
Further program milestones and timing will be announced as development and regulatory pathways progress.
About DePuy Synthes
DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement to the millions of patients we serve. Our solutions—including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine—alongside the VELYS™ Digital Surgery portfolio, are designed to support improved patient care and deliver clinical and economic value to healthcare systems worldwide. Building on a legacy of product innovation and industry firsts, we continue to shape the orthopaedic landscape through advancements in medical technologies and digital surgery across the continuum of care to Keep People Moving today and tomorrow.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://www.jnjmedtech.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential acquisition of SCAP Hologram’s RF Technology. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Ireland Unlimited Company and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the acquisition; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Neither DePuy Ireland Unlimited Company nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
© Johnson & Johnson and its affiliates 2026. All rights reserved.
Agreement between SCAP Hologram, Kyniska Robotics, MinMaxMedical and DePuy Ireland Unlimited Company.